SummaryBackgroundProphylaxis of HBV recurrence is critical after liver transplantation in HBV patients. Despite new prophylactic schemes, most European LT centres persist on a conservative approach combining hepatitis B immunoglobulin (HBIG) and nucleos(t)ides analogues (NA).AimThis setting prompted the European Liver Intestine Transplantation Association (ELITA) to look for a consensus on the prevention of HBV recurrence.MethodsBased on a 4‐round Delphi process, ELITA investigated 16 research questions and established 50 recommendations.ResultsProphylaxis should be driven according to 3 simplified risk groups: Low and high virological risk patients, with undetectable and detectable HBV DNA pre‐LT, respectively, and special populations (HDV, HCC, poorly adherent patients). In low‐risk patients, short‐term (4 weeks) combination of third‐generation NA+ HBIG, or third generation NA monotherapy can be considered as prophylactic options. In high‐risk patients, HBIG can be discontinued once HBV DNA undetectable. Combined therapy for 1 year is advised. HBV‐HCC patients should be treated according to their virological risk. In HDV/HBV patients, indefinite dual prophylaxis remains the gold standard. Full withdrawal of HBV prophylaxis following or not HBV vaccination should only be attempted in the setting of clinical trials. Organs from HBsAg+ve donors may be considered after assessment of risks, benefits, and patient consent. They should not be used if HDV is present. In poorly adherent patients, dual long‐term prophylaxis is recommended. Budget impact analysis should be taken into account to drive prophylactic regimen.ConclusionsThese ELITA recommendations should stimulate a more rational and homogeneous approach to HBV prophylaxis across LT programs.